Pfizer said it will buy migraine drug maker Biohaven Pharmaceutical Holding Company for about $11.6 billion in cash.
Through the deal, Pfizer will gain access to Biohaven's approved drug Rimegepant that belong to a class of migraine drugs known as calcitonin gene-related peptide inhibitors.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: